

ZERVIAE- cetirizine for solution
Harrow Eye, LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ZERVIAE[®] safely and effectively. See full prescribing information for ZERVIAE[®].

ZERVIAE[®] (cetirizine ophthalmic solution) 0.24%, for topical ophthalmic use

Initial U.S. Approval: 1995

-----**RECENT MAJOR CHANGES**-----

Dosage and Administration (2)

2/2020

Warnings and Precautions (5.1)

2/2020

-----**INDICATIONS AND USAGE**-----

ZERVIAE[®] (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis. (1)

-----**DOSAGE AND ADMINISTRATION**-----

The recommended dose is one drop in each affected eye twice daily. (2)

-----**DOSAGE FORMS AND STRENGTHS**-----

Ophthalmic solution: 2.4 mg cetirizine in 1 mL sterile solution (0.24%). (3)

-----**CONTRAINDICATIONS**-----

None. (4)

-----**WARNINGS AND PRECAUTIONS**-----

Contamination of Tip and Solution. To prevent contaminating the dropper tip and solution, advise patients not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container. (5.1)

-----**ADVERSE REACTIONS**-----

The most common adverse reactions (1-7%) were ocular hyperemia, instillation site pain, and visual acuity reduced. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Harrow at 1-833-4HARROW(427769) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Contamination of Tip and Solution

5.2 Contact Lens Wear

6 ADVERSE REACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

ZERVIA[®] (cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

2 DOSAGE AND ADMINISTRATION

The recommended dosage of ZERVIA[®] is to instill one drop in each affected eye twice daily (approximately 8 hours apart).

The single-use containers are to be used immediately after opening and can be used to dose both eyes. Discard the single-use container and any remaining contents after administration. The single-use containers should be stored in the original foil pouch until ready to use.

3 DOSAGE FORMS AND STRENGTHS

Cetirizine ophthalmic solution, 0.24% is a sterile, buffered, clear, colorless aqueous solution containing cetirizine 0.24% (equivalent to cetirizine hydrochloride 0.29%).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Contamination of Tip and Solution

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container in order to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-

dose bottle closed when not in use. Discard the single-use container after using in each eye.

5.2 Contact Lens Wear

Patients should be advised not to wear a contact lens if their eye is red.

ZERVIA[®] should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIA[®]. The preservative in ZERVIA[®], benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIA[®].

6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates in practice.

In seven clinical trials, patients with allergic conjunctivitis or those at a risk of developing allergic conjunctivitis received one drop of either cetirizine (N=511) or vehicle (N=329) in one or both eyes. The most commonly reported adverse reactions occurred in approximately 1–7% of patients treated with either ZERVIA[®] or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There were no adequate or well-controlled studies with ZERVIA[®] in pregnant women.

Cetirizine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Data

Animal Data

Cetirizine was not teratogenic in mice, rats, or rabbits at oral doses up to 96, 225, and 135 mg/kg, respectively (approximately 1300, 4930, and 7400 times the maximum recommended human ophthalmic dose (MRHOD), on a mg/m² basis).

8.2 Lactation

Risk Summary

Cetirizine has been reported to be excreted in human breast milk following oral administration. Multiple doses of oral dose cetirizine (10 mg tablets once daily for 10 days) resulted in systemic levels (Mean C_{max} = 311 ng/mL) that were 100 times higher than the observed human exposure (Mean C_{max} = 3.1 ng/mL) following twice daily administration of cetirizine ophthalmic solution 0.24% to both eyes for one week [see *Clinical Pharmacology* (12.3)]. Comparable bioavailability has been found between the tablet and syrup dosage forms. However, it is not known whether the systemic

absorption resulting from topical ocular administration of ZERVIAE[®] could produce detectable quantities in human breast milk.

There is no adequate information regarding the effects of cetirizine on breastfed infants, or the effects on milk production to inform risk of ZERVIAE[®] to an infant during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZERVIAE[®] and any potential adverse effects on the breastfed child from ZERVIAE[®].

8.4 Pediatric Use


The safety and effectiveness of ZERVIAE[®] (cetirizine ophthalmic solution) 0.24% has been established in pediatric patients two years of age and older. Use of ZERVIAE[®] in these pediatric patients is supported by evidence from adequate and well-controlled studies of ZERVIAE[®] in pediatric and adult patients.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

11 DESCRIPTION

ZERVIAE[®] is a sterile ophthalmic solution containing cetirizine, which is a histamine-1 (H₁) receptor antagonist, for topical administration to the eyes. Cetirizine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 461.8 and a molecular formula of C₂₁H₂₅ClN₂O₃•2HCl. The chemical structure is presented below:



Chemical Name:

(*RS*)-2-[2-[4-[(4-Chlorophenyl) phenylmethyl] piperazin-1-yl] ethoxy] acetic acid, dihydrochloride

Each mL of ZERVIAE[®] contains an active ingredient [cetirizine 2.40 mg (equivalent to 2.85 mg of cetirizine hydrochloride)] and the following inactive ingredients: benzalkonium chloride 0.010% (preservative); glycerin; sodium phosphate, dibasic; edetate disodium; polyethylene glycol 400; polysorbate 80; hypromellose; hydrochloric acid/sodiumhydroxide (to adjust pH); and water for injection. ZERVIAE[®] solution has a pH of approximately 7.0 and osmolality of approximately 300 mOsm/kg.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

ZERVIAE[®], an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models. *In vivo* and *ex vivo* animal models have shown negligible anticholinergic and antiserotonergic activity. *In vitro* receptor binding studies have shown no measurable affinity for other than H1 receptors.

12.3 Pharmacokinetics

In healthy subjects, bilateral topical ocular dosing of one drop of ZERVIAE[®] resulted in a mean cetirizine plasma C_{max} of 1.7 ng/mL following a single dose and 3.1 ng/mL after twice-daily dosing for one week. The observed mean terminal half-life of cetirizine was 8.6 hours following a single dose and 8.2 hours after twice-daily dosing of ZERVIAE[®] for one week.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity

In a 2-year carcinogenicity study in rats, orally administered cetirizine was not carcinogenic at dietary doses up to 20 mg/kg (approximately 550 times the MRHOD, on a mg/m² basis). In a 2-year carcinogenicity study in mice, cetirizine caused an increased incidence of benign liver tumors in males at a dietary dose of 16 mg/kg (approximately 220 times the MRHOD, on a mg/m² basis). No increase in the incidence of liver tumors was observed in mice at a dietary dose of 4 mg/kg (approximately 55 times the MRHOD, on a mg/m² basis). The clinical significance of these findings during long-term use of cetirizine is not known.

Mutagenesis

Cetirizine was not mutagenic in the Ames test or in an *in vivo* micronucleus test in rats.

Cetirizine was not clastogenic in the human lymphocyte assay or the mouse lymphoma assay.

Impairment of Fertility

In a fertility and general reproductive performance study in mice, cetirizine did not impair fertility at an oral dose of 64 mg/kg (approximately 875 times the MRHOD on a mg/m² basis).

14 CLINICAL STUDIES

The efficacy of ZERVIAE[®] (cetirizine ophthalmic solution) 0.24% was established in three randomized, double-masked, placebo-controlled, conjunctival allergen challenge (CAC) clinical trials in patients with a history of allergic conjunctivitis. Onset and duration of action were evaluated in two of these trials in which patients were randomized to receive ZERVIAE[®] or vehicle ophthalmic solutions. Patients were evaluated with an ocular itching severity score ranging from 0 (no itching) to 4 (incapacitating itch) at several time points after CAC administration. Table 1 displays data from the mean ocular

itching severity scores after ocular administration of an antigen using the CAC model. A one unit difference compared to vehicle is considered a clinically meaningful change in the ocular itching severity score.

Patients treated with ZERVIA[®] demonstrated statistically and clinically significantly less ocular itching compared to vehicle at 15 minutes and 8 hours after treatment.

Table 1 Itching Scores in the ITT Population by Treatment Group and Treatment Difference

	Study 1				Study 2			
Statistics	15 minutes post-treatment		8 hours post-treatment		15 minutes post-treatment		8 hours post-treatment	
	ZERVIA	Vehicle	ZERVIA	Vehicle	ZERVIA	Vehicle	ZERVIA	Vehicle
	N=50	N=50	N=50	N=50	N=51	N=50	N=51	N=50
3 Minute Post-CAC								
Mean	1.00	2.38	1.76	2.69	1.01	2.54	1.94	2.86
Treatment Difference (95% CI) ¹	-1.38 (-1.72, -1.05)*		-0.93 (-1.26, -0.61)*		-1.53 (-1.92, -1.15)*		-0.92 (-1.25, -0.58)*	
5 Minute Post-CAC								
Mean	1.18	2.43	1.85	2.74	1.17	2.51	2.03	2.94
Treatment Difference (95% CI) ¹	-1.25 (-1.58, -0.91)*		-0.89 (-1.24, -0.54)*		-1.34 (-1.71, -0.97)*		-0.90 (-1.23, -0.57)*	
7 Minute Post-CAC								
Mean	1.11	2.11	1.54	2.53	1.15	2.23	1.82	2.66
Treatment Difference (95% CI) ¹	-1.00 (-1.35, -0.65)*		-0.99 (-1.40, -0.59)*		-1.07 (-1.46, -0.69)*		-0.84 (-1.21, -0.48)*	
¹ Treatment difference values shown are the group mean active minus the group mean vehicle at each post-CAC time point.								
* p<0.05								

16 HOW SUPPLIED/STORAGE AND HANDLING

ZERVIA[®] is a sterile, buffered, clear, colorless aqueous solution containing cetirizine 0.24% (equivalent to cetirizine hydrochloride 0.29%) supplied in a white low-density polyethylene multi-dose ophthalmic bottle with a low-density polyethylene dropper tip and a white polypropylene cap. ZERVIA[®] is supplied in a 7.5 mL bottle that contains 5 mL and a 10 mL bottle that contains 7.5 mL cetirizine ophthalmic solution, 2.40 mg [equivalent to 2.85 mg cetirizine hydrochloride in one mL solution]. ZERVIA[®] is also supplied in 5 low-density polyethylene 0.2 mL single-use containers within a foil pouch.

Carton of 30 single-use containers NDC 82667-015-24

Storage: Store at 15°C to 25°C (59°F to 77°F).

Single-use containers should be stored in the original foil pouch.

17 PATIENT COUNSELING INFORMATION

- Risk of Contamination: Advise patients not to touch dropper tip to eyelids or surrounding areas, as this may contaminate the dropper tip and ophthalmic solution. Advise patients to keep the bottle closed when not in use. Advise patients to discard single-use containers after each use.
- Concomitant Use of Contact Lenses: Advise patients not to wear contact lenses if their eyes are red. Advise patients that ZERVIA[®] should not be used to treat contact lens-related irritation. Advise patients to remove contact lenses prior to instillation of ZERVIA[®]. The preservative in ZERVIA[®] solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIA[®].
- Administration: Advise patients that the solution from one single-use container is to be used immediately after opening. Advise patients that the single-use container can be used to dose both eyes. Discard the single-use container and remaining contents immediately after administration.
- Storage of Single-use Containers: Instruct patients to store single-use containers in the original foil pouch until ready to use.

Rev 11/2024

Manufactured for:

Harrow Eye, LLC TM
Nashville, TN USA

U.S. Patents: 8,829,005; 9,254,286; 9,750,684; 9,993,471

Principal Display Panel - 2.5 mL Carton Label

NDC 82667-015-24

ZERVIA[®]


*(cetirizine ophthalmic
solution) 0.24%*


30 single use containers

**6 pouches x 5 single-use containers
(0.2 mL each)**

**FOR TOPICAL
OPHTHALMIC USE**

Rx Only HARROW[®] Sterile





ZERViate

cetirizine for solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:82667-015
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
CETIRIZINE (UNII: YO7261ME24) (CETIRIZINE - UNII:YO7261ME24)	CETIRIZINE	2.4 mg in 1 mL

Inactive Ingredients	
Ingredient Name	Strength
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)	
EDETATE DISODIUM (UNII: 7FLD91C86K)	
GLYCERIN (UNII: PDC6A3C0OX)	
HYPROMELLOSE 2910 (4000 MPA.S) (UNII: RN3152OP35)	
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
WATER (UNII: 059QF0KO0R)	

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:82667-015-24	1 in 1 CARTON	04/30/2025	
1		30 in 1 POUCH		
1		2.5 mL in 1 VIAL, SINGLE-USE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

NDA	NDA208694	04/30/2025	
-----	-----------	------------	--

Labeler - Harrow Eye, LLC (118526951)

Establishment

Name	Address	ID/FEI	Business Operations
Excelvision		274234566	manufacture(82667-015) , analysis(82667-015) , label(82667-015) , pack(82667-015)

Revised: 4/2025

Harrow Eye, LLC